Interaction of thymic peptide thymosin alpha 1 with vasoactive intestinal peptide (VIP) receptors.

Calvo JR, Goberna R, Guerrero JM

Bioscience reports1 Aug 1986Cited by 4 (Europe PMC)

PMID3028522DOI10.1007/bf01116540PepBankPUB-03028522

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueActivity measurement
In rat blood mononuclear cells and liver plasma membranes, thymosin alpha‑1 inhibited the specific binding of [125I]VIP.
In plain wordsIn lab tests on rat cells and membranes, thymosin alpha‑1 reduced the binding of VIP to its receptors.
Peptide
Thymosin alpha-1
Outcome
DecreaseInhibition of [125I]VIP specific binding
Study
ratn: not reported in source
Rat blood mononuclear cells and liver plasma membranes
Comparator
VIP
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
10(-9) to 3 X 10(-7) MAs given in this study (rat).
Source sentences
Summary
Thymic peptide thymosin alpha 1 (10(-9) to 3 X 10(-7) M) is shown to inhibit the specific binding of [125I]VIP to rat blood mononuclear cells and liver plasma membranes.
Report a problemFND-0302852201
02LabEx vivo tissueActivity measurement
Thymosin alpha‑1 was 160 times less potent than VIP in blood mononuclear cells and 6250 times less potent in liver plasma membranes at inhibiting [125I]VIP binding.
In plain wordsIn lab tests on rat cells, thymosin alpha‑1 blocked VIP binding far less strongly than VIP itself did.
Peptide
Thymosin alpha-1
Outcome
DecreasePotency relative to VIP at inhibiting [125I]VIP binding
Study
ratn: not reported in source
Rat blood mononuclear cells and liver plasma membranes
Comparator
VIP
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Measurements
Potency relative to VIP (times less potent)
160 fold
blood mononuclear cells
Potency relative to VIP (times less potent)
6250 fold
liver plasma membranes
Source sentences
Summary
Thymosin alpha 1 was 160 and 6250 times less potent that VIP at inhibiting [125I]VIP binding to blood mononuclear cells and liver plasma membranes, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Thymic peptide thymosin alpha 1 (10(-9) to 3 X 10(-7) M) is shown to inhibit the specific binding of [125I]VIP to rat blood mononuclear cells and liver plasma membranes.
Report a problemFND-0302852202
03LabEx vivo tissueActivity measurement
Thymosin alpha‑1 weakly stimulated adenylate cyclase activity, with an efficacy of about 25% in blood mononuclear cells and 27% in liver plasma membranes relative to native VIP.
In plain wordsIn lab tests on rat cells, thymosin alpha‑1 only weakly switched on adenylate cyclase compared with native VIP.
Peptide
Thymosin alpha-1
Outcome
IncreaseAdenylate cyclase stimulation
Study
ratn: not reported in source
Rat blood mononuclear cells and liver plasma membranes
Comparator
VIP
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
10(-10) to 10(-7) MAs given in this study (rat).
Measurements
Efficacy relative to VIP
≈ 25%
blood mononuclear cells
Efficacy relative to VIP
≈ 27%
liver plasma membranes
Source sentences
Summary
Thymosin alpha 1 (10(-10) to 10(-7) M) was weak in stimulating adenylate cyclase activity. Its efficacy is about 25% and 27% that of native VIP in blood mononuclear cells and liver plasma membranes, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Thymic peptide thymosin alpha 1 (10(-9) to 3 X 10(-7) M) is shown to inhibit the specific binding of [125I]VIP to rat blood mononuclear cells and liver plasma membranes.
Report a problemFND-0302852203
04LabEx vivo tissueActivity measurement
VIP was far more potent than thymosin alpha 1 at inhibiting [125I]VIP binding, by 160-fold in blood mononuclear cells and 6250-fold in liver plasma membranes.
In plain wordsIn lab tests on rat cells, VIP blocked its own receptor binding much more strongly than thymosin alpha 1 did.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreasePotency at inhibiting [125I]VIP binding versus thymosin alpha 1
Study
ratn: not reported in source
Rat blood mononuclear cells and liver plasma membranes
Comparator
Thymosin alpha 1
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Measurements
Potency relative to thymosin alpha 1
160 fold
blood mononuclear cells
Potency relative to thymosin alpha 1
6250 fold
liver plasma membranes
Source sentences
Summary
Thymosin alpha 1 was 160 and 6250 times less potent that VIP at inhibiting [125I]VIP binding to blood mononuclear cells and liver plasma membranes, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Thymic peptide thymosin alpha 1 (10(-9) to 3 X 10(-7) M) is shown to inhibit the specific binding of [125I]VIP to rat blood mononuclear cells and liver plasma membranes.
Report a problemFND-0302852204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
10 Oct 2026, 08:55 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 12:41 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:03 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.